VWF and thrombotic thrombocytopenic purpura: Recently, the addition of caplacizumab, an anti-von Willebrand factor humanized immunoglobulin fragment, to plasma exchange and immunosuppression, leads to reduced incidence of TTP-related death, TTP recurrence, stroke, and other thromboembolic events [60].